About this trial
This study is a Phase III, global, randomised double-blind trial of birtamimab plus standard of care vs placebo plus standard of care in Mayo Stage IV AL amyloid patients
Patient Profile
The target population for this study are Mayo Stage IV AL amyloid patients.
Where’s this trial being run?
Beaumont Hospital and Cork University Hospital
Can I join this study / trial?
The first thing you do is to talk to your doctor and/or the cancer trials research team in your hospital. The contact details for the cancer trials research units in Ireland is here.
Why not Print this page and bring it with you. It will help your doctor and research team advise you.
Print this pageFor more detailed information
Click HereQuestions?
Here’s a list of questions you may have for your doctor or local cancer research team.
QuestionsSummary Data
| Name: | AFFIRM-AL |
|---|---|
| Number: | 22-13 |
| Full Title: | AFFIRM-AL: Global Phase 3 randomised double-blind trial of birtamimab plus standard of care vs placebo plus standard of care in Mayo Stage IV AL amyloid patients |
| Principal Investigator: | Dr John Quinn |
|---|---|
| Type: | Industry Sponsored |
| Sponsor: | Prothena |
| Recruitment Started: |
Global: 30-Aug-2021 Ireland: TBC |
| Global Recruitment Target: | 150 |
|---|---|
| Ireland Recruitment Target: | 4 |